Head and neck cancers are important to human life and health in both developed and underdeveloped countries. Management of established cancers is difficult, and there is great interest in evaluating methods to prevent these tumors from developing.
Methods
The biology of carcinogenesis, including field carcinogenesis, is reviewed, together with the biology and pharmacology of the retinoids. Intervention studies of premalignant lesions have led to prospective clinical trials of the capability of various retinoids to reduce the incidence of new second cancers.
Results
High-dose 13-cis-retinoic acid (13cRA) has significant activity in reversing oral leukoplakia but at a cost of substantial toxicity, and relapses occur early. An ongoing intergroup trial is underway to evaluate the capacity of low-dose (30 mg/d) 13cRA given for three years to reduce the incidence of second primary tumors in patients with “cured” squamous head and neck cancers.
Conclusions
Molecular studies of loss of heterozygosity and p53 gene mutations are advancing our understanding of field carcinogenesis and the biology, pharmacology, and effects of the retinoids used in cancer prevention. Translation of early clinical trials into large-scale intervention trials to prevent
Get full access to this article
View all access options for this article.
References
1.
ParkinD.M., PisaniP., FerlayJ.Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer.1993; 54: 594–606.
2.
WingoP.A., TongT., BoldenS.Cancer statistics. CA Cancer J Clin.1995; 45: 8–30.
3.
BlotW.J., DevesaS.S., McLaughlinJ.K.Oral and pharyngeal cancers. Cancer Surv.1994; 19–20: 23–42.
4.
VokesE.E., WeichselbaumR.R., LippmanS.M.Head and neck cancer. N Engl J Med.1993; 328: 184–194.
5.
LippmanS.M., HongW.K.Chemotherapy and chemoprevention. In: MyersE.N., SuenJ.Y., eds. Cancer of the Head and Neck.3rd ed.Philadelphia, Pa: WB Saunders Co; 1995: 782–804.
6.
ClaymanG.L., LippmanS.M., LaramoreG.Head and neck cancer. In: HollandJ.F., FreiE., BastR.C.Jr, eds. Cancer Medicine.4th ed.Philadelphia, Pa: Williams & Wilkins; 1997: 1648–1710.
7.
SpornM.B., LippmanS.M.Chemoprevention of cancer. In: HollandJ.F., FreiE., BastR.C.Jr, eds. Cancer Medicine.4th ed.Philadelphia, Pa: Williams & Wilkins; 1997: 495–508.
8.
HongW.K., LippmanS.M., HittelmanW.N.Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res.1995; 1: 677–686.
9.
Van der RietP., NawrozH., HrubanR.H.Frequent loss of chromosome 9p21–22 early in head and neck cancer progression. Cancer Res.1994; 54: 1156–1158.
10.
MaoL., LeeJ.S., FanY.H.Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med.1996; 2: 682–685.
11.
SlaughterD.P., SouthwickH.W., SmejkalW.“Field cancerization” in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer.1953; 6: 963–968.
12.
BrennanJ.A., BoyleJ.O., KochW.M.Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med.1995; 332: 712–717.
13.
ChungK.Y., MukhopadhyayT., KimJ.Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res.1993; 53: 1676–1683.
14.
BediG.C., WestraW.H., GabrielsonE.Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res.1996; 56: 2484–2487.
15.
HofmannC., EicheleG.Retinoids in development. In: SpornM.B., RobertsA.B., GoodmanD.S., eds. The Retinoids: Biology, Chemistry and Medicine.2nd ed.New York, NY: Raven Press; 1994: 387–442.
16.
MeansA.L., GudasL.J.The roles of retinoids in vertebrate development. Annu Rev Biochem.1995; 64: 201–233.
17.
MangelsdorfD.J., UmesonoK., EvansR.M.The retinoid receptors. In: SpornM.B., RobertsA.B., GoodmanD.S., eds. The Retinoids.New York, NY: Raven Press; 1994: 319–349.
MangelsdorfD.J., ThummelC., BeatoM.The nuclear receptor superfamily: the second decade. Cell.1995; 83: 835–839.
20.
MangelsdorfD.J., EvansR.M.The RXR heterodimers and orphan receptors. Cell.1995; 83: 841–850.
21.
RoyB., TanejaR., ChambonP.Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR-alpha)-, RAR-beta-, or RAR-gamma-selective ligand in combination with a retinoid X receptor-specific ligand. Mol Cell Biol.1995; 15: 6481–6487.
22.
LookJ., LandwehrJ., BauerF.Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid. Am J Physiol.1995; 269: E91–E98.
23.
TanejaR., BouilletP., BoylanJ.F.Reexpression of retinoic acid receptor (RAR) gamma or overexpression of RAR alpha or RAR beta in RAR-gamma-null F9 cells reveals a partial functional redundancy between the three RAR types. Proc Natl Acad Sci U S A.1995; 92: 7854–7858.
24.
RobertsonK.A., EmamiB., MuellerL.Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol Cell Biol.1992; 12: 3743–3749.
25.
KastnerP., MarkM., ChambonP.Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life. Cell.1995; 83: 859–869.
26.
CornicM., AgadirA., DegosL.Retinoids and differentiation treatment: a strategy for treatment in cancer. Anticancer Res.1994; 14: 2339–2346.
27.
FanjulA., DawsonM.I., HobbsP.D.A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature.1994; 372: 107–111.
28.
NagpalS., AthanikarJ., ChandraratnaR.A.Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem.1995; 270: 923–927.
29.
ChenJ.Y., PencoS., OstrowskiJ.RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J.1995; 14: 1187–1197.
30.
KameiY., XuL., HeinzelT.A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell.1996; 85: 403–414.
31.
BlanerW.S., OlsonJ.A.Retinol and retinoic acid metabolism. In: SpornM.B., RobertsA.B., GoodmanD.S., eds. The Retinoids: Biology, Chemistry and Medicine.2nd ed.New York, NY: Raven Press; 1994: 229–257.
32.
SopranoD.R., BlanerW.S.Plasma retinol binding protein. In: SpornM.B., RobertsA.B., GoodmanD.S., eds. The Retinoids: Biology, Chemistry and Medicine.2nd ed.New York, NY: Raven Press; 1994; 257–282.
ChaiX., BoermanM.H., ZhaiY.Cloning of a cDNA for liver microsomal retinol dehydrogenase: a tissue-specific, short-chain alcohol dehydrogenase. J Biol Chem.1995; 270: 3900–3904.
35.
OngD.E., NewcomerM.E., ChytilF.Cellular retinoid-binding proteins. In: SpornM.B., RobertsA.B., GoodmanD.W., eds. The Retinoids: Biology, Chemistry and Medicine.2nd ed.New York, NY: Raven Press; 1994: 283–318.
36.
BoylanJ.F., GudasL.J.The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem.1992; 267: 21486–21491.
37.
VermaA.K., ShoemakerA., SimsimanR.Expression of retinoic acid nuclear receptors and tissue transglutaminase is altered in various tissues of rats fed a vitamin A-deficient diet. J Nutr.1992; 122: 2144–2152.
38.
KatoS., ManoH., KumazawaT.Effect of retinoid status on alpha, beta and gamma retinoic acid receptor mRNA levels in various rat tissues. Biochem J.1992; 286: 755–760.
39.
HaqR., PfahlM., ChytilF.Retinoic acid affects the expression of nuclear retinoic acid receptors in tissues of retinol-deficient rats. Proc Natl Acad Sci U S A.1991; 88: 8272–8276.
40.
VahlquistA., AnderssonE., CobleB.I.Increased concentrations of 3, 4-didehydroretinol and retinoic acid-binding protein (CRABPII) in human squamous cell carcinoma and keratoacanthoma but not in basal cell carcinoma of the skin. J Invest Derm.1996; 106: 1070–1074.
41.
XuX.C., ZileM.H., LippmanS.M.Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res.1995; 55: 5507–5511.
42.
LotanR., XuX.C., LippmanS.M.Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med.1995; 332: 1405–1410.
43.
OngD.E., GoodwinW.J., JesseR.H.Presence of cellular retinol and retinoic acid-binding proteins in epidermoid carcinoma of the oral cavity and oropharynx. Cancer.1982; 49: 1409–1412.
44.
de TheH., ChomienneC., LanotteM.The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature.1990; 347: 558–561.
45.
DejeanA., de TheH.Hepatitis B virus as an insertional mutagene in a human hepatocellular carcinoma. Mol Biol Med.1990; 7: 213–222.
46.
ZhangX.K., LiuY., LeeM.O.A specific defect in the retinoic acid response associated with human lung cancer cell lines. Cancer Res.1994; 54: 5663–5669.
47.
MoghalN., NeelB.G.Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer. Mol Cell Biol.1995; 15: 3945–3959.
48.
SkredeB., LieS.O., BlomhoffR.Uptake and storage of retinol and retinyl esters in bone marrow of children with acute myeloid leukemia treated with high-dose retinyl palmitate. Eur J Haematol.1994; 52: 140–144.
49.
SkredeB., BlomhoffR., MaelandsmoG.M.Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo. Eur J Clin Invest.1992; 22: 229–234.
MayneS.T., LippmanS.M.Retinoids and carotenoids. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.5th ed.Philadelphia, Pa: JB Lippincott Co; 1997: 585–599.
52.
StichH.F., RosinM.P., HornbyA.P.Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer.1988; 42: 195–199.
53.
ZaridzeD., EvstifeevaT., BoyleP.Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol.1993; 3: 225–234.
54.
BennerS.E., WinnR.J., LippmanS.M.Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study. J Natl Cancer Inst.1993; 85: 44–47.
55.
HongW.K., EndicottJ., ItriL.M.13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med.1986; 315: 1501–1505.
56.
LippmanS.M., BatsakisJ.G., TothB.B.Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med.1993; 328: 15–20.
57.
StichH.F., HornbyA.P., MathewB.Response of oral leukoplakias to the administration of vitamin A. Cancer Lett.1988; 40: 93–101.
58.
HanJ., JiaoL., LuY.Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo.1990; 4: 153–160.
59.
ChiesaF., TradatiN., MarazzaM.Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem.1993; 17(suppl F): 255–261.
60.
VikramB.Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol.1984; 110: 564–565.
61.
LippmanS.M., HongW.K.Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with earlystage disease. Int J Rad Oncol Biol Phys.1989; 17: 691–694.
62.
HongW.K., LippmanS.M., ItriL.M.Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med.1990; 323: 795–801.
63.
BennerS.E., PajakT.F., LippmanS.M.Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst.1994; 86: 140–141.
64.
PastorinoU., InfanteM., MaioliM.Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol.1993; 11: 1216–1222.
65.
BollaM., LefurR., Ton VanJ.Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx: results of a multicentric double-blind randomised study. Eur J Cancer.1994; 30A: 767–772.
66.
BennerS.E., PajakT.F., StetzJ.Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer. J Natl Cancer Inst.1994; 86: 1799–1801.
67.
XuX.C., RoJ.Y., LeeJ.S.Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res.1994; 54: 3580–3587.
68.
LippmanS.M., ShinD.M., LeeJ.J.p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res.1995; 55: 16–19.
69.
ShinD.M., LeeJ.S., LippmanS.M.p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst.1996; 88: 519–529.
